Silexion cuts warrant price to $0.2603 to raise about $0.84 million
On September 28, 2026, Silexion Therapeutics agreed to lower the exercise price of 3,216,928 series E warrants from $0.65 to $0.2603 per share, with holders expected to exercise for about $0.84 million in gross proceeds before fees. In return, the company will issue new Series F and Series G warrants covering up to 6,433,856 ordinary shares, which adds potential dilution for existing shareholders.
Key points
- Holders of 3,216,928 existing warrants agreed to exercise at a reduced price of $0.2603, down from $0.65.
- Expected gross proceeds from the exercises are about $0.84 million, before placement agent fees and offering expenses.
- New warrants cover 6,433,856 ordinary shares, split between 3,216,928 Series F and 3,216,928 Series G warrants.
- Closing is expected on or about September 29, 2026, and H.C. Wainwright & Co. is the placement agent with a 7.0% cash fee plus a 1.0% management fee.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.